A phase 2 clinical program for the third generation of the iLink therapy to treat keratoconus is underway, according to a Glaukos press release.
The third generation of the cross-linking platform will build on previous versions to customize therapeutic capabilities and improve the patient experience.
The program will include two multicenter randomized controlled trials that will evaluate the safety and efficacy of patient-specific customized vs. non-customized treatment patterns for cross-linking, as well as an investigational laser-based bioactivation system, the release said. Both trials will